{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibl74dfz6xtyrwvao73b7ggkmo2ymeiw2et3edgg57d3whxeotiv4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mesgi3kmau52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/02/13/lilly-glp1-obesity-340b-nih-hiv-aids/?utm_campaign=rss",
  "publishedAt": "2026-02-13T14:36:17.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "And other pharma news from the Pharmalot campus today",
  "title": "STAT+: Pharmalittle: We’re reading about Lilly bulking up on weight-loss drugs, scrutiny of a 340B contractor, and more",
  "updatedAt": "2026-02-13T14:36:20.000Z"
}